Moore Duncan 4

4 · ASP Isotopes Inc. · Filed Apr 17, 2026

AI-generated summary of this filing

Updated Apr 18, 2026

ASP Isotopes (ASPI) Director Moore Duncan Sells 11,642 Shares

What Happened

Moore Duncan, an independent director of ASP Isotopes Inc. (ASPI) and member of the QLE Structuring and Strategic Transactions Committee, reported multiple equity transactions. He received two restricted stock awards (25,469 shares on 2025-11-12 and 36,548 shares on 2025-12-18) and later sold 11,642 shares in an open-market/private sale on 2026-04-16 for total proceeds of $60,597 (weighted average price $5.21).
The sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2025, and the disposition includes shares sold to satisfy income tax liabilities related to the vesting of a previously granted restricted stock award.

Key Details

Transaction dates: awards on 2025-11-12 (25,469 shares) and 2025-12-18 (36,548 shares); sale on 2026-04-16 (11,642 shares).
Sale price: weighted average $5.21; individual sale prices ranged from $5.055 to $5.52. Total proceeds reported: $60,597.
Share ownership after the transactions: not specified in the data provided in this summary (not disclosed here).
Notable footnotes: F1/F2 = restricted stock awards tied to director service; F3 = sale under a Rule 10b5-1 plan and includes shares sold to cover tax withholding from vesting; F4 = weighted-average price with available range and offer to provide per-price breakdown on request.
Timeliness: the open-market sale (4/16/2026) was filed the next day (4/17/2026). The awards dated 11/12/2025 and 12/18/2025 were reported in this Form 4 filed on 2026-04-17 and therefore appear to be reported well after the grant dates.

Context

Awards (A) are compensation-related restricted stock grants and do not indicate an out-of-pocket purchase decision by the insider; they reflect director compensation.
The sale (S) was made under a pre-established 10b5-1 trading plan and includes shares sold to meet tax obligations from vesting—common and typically routine for insiders after grants vest.
For a precise breakdown of how many shares were sold at each price within the reported range, the filing notes the reporting person will provide that information to the company, any shareholder, or the SEC staff upon request.

Form 4

Period: 2025-11-12

Director

Transactions

Footnotes (4)

[F1]Award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc. on the QLE Structuring and Strategic Transactions Committee.
[F2]2025 annual award of shares of restricted stock in connection with the reporting person's service as an independent director of ASP Isotopes Inc.
[F3]The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 31, 2025 and includes an amount for the purpose of satisfying the reporting person's income tax liabilities resulting from the vesting of a previously granted restricted stock award pursuant to an issuer equity incentive plan.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.055 to $5.52, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2.

Signature

/s/ Donald Ainscow, as attorney-in-fact|2026-04-17

1 file